Primary Immunodeficiency Diseases clinical trials at UC Irvine

2 in progress, 0 open to eligible people

Showing trials for

  • About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

    Sorry, in progress, not accepting new patients

    The main aim of this study is to learn if TAK-881 is safe and well tolerated during long-term use in adults and children with PIDD who are eligible and completed study TAK-881-3001 (NCT05755035). The participants will receive the first dose of TAK-881 immunoglobulin (IgG) infusion at the same dosage as the last dose administered in study TAK-881-3001 (NCT05755035). After the first TAK-881 infusion in study TAK-881-3002, the dosing interval (can be adjusted by participant/caregiver) and/or the dose of TAK-881 can be adjusted by the study doctor to every 2, 3 or 4 weeks at scheduled site visits. Participants will visit the clinic every 12 weeks until the End of Study (EOS) visit.

    Irvine, California and other locations

  • Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

    Sorry, in progress, not accepting new patients

    Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases

    Irvine, California and other locations

Our lead scientists for Primary Immunodeficiency Diseases research studies include .

Last updated: